W
WAVEMAN · COMPANY
SPRY · Ars Pharmaceuticals, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

SPRY

ARS Pharmaceuticals, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001671858
FORM 144 · 10☆ WATCH
INSIDER NET · 180D
-$283.6K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
114
13F, latest reported quarter
REVENUE GROWTH
-5.5%
XBRL, annual
NET MARGIN
-203.3%
CONVERSIONS · 180D
1
codes C/M, not in net · $37.5K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$283.6K over 180 days
-$283.6K over 90 days
below 52% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
114 funds added or opened last quarter
more than 70% of Pharma & Biotech
REVENUE
-5.5% year over year
below 65% of Pharma & Biotech
MARGIN
-203.3% net margin
below 73% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
10 insiders have filed intent to sell ($2.2M) and have not sold yet.
114 funds added or opened positions in the latest 13F quarter, of 211 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -47.7%
-47.7%12M
-54%-30%-6%+17%2025-092025-102025-122026-032026-052026-072026-09 2025-11-12 · Chakma Justin sold $1.2M2025-11-12 · Chakma Justin sold $267.3K2026-06-12 · Karas Eric sold $250.0K2025-11-13 · Dorsey Brian sold $190.1K2026-06-12 · Fitzpatrick Alexander A sold $33.5K2026-09-03 · RICHARD LOWENTHAL filed to sell $115.6K2026-09-02 · RICHARD LOWENTHAL filed to sell $5.0K2026-09-01 · SARINA TANIMOTO filed to sell $272.8K2026-08-31 · SARINA TANIMOTO filed to sell $368.1K2026-08-20 · RICHARD LOWENTHAL filed to sell $148.2K2026-08-20 · SARINA TANIMOTO filed to sell $148.0K2026-08-19 · RICHARD LOWENTHAL filed to sell $322.3K2026-08-19 · SARINA TANIMOTO filed to sell $161.2K2026-08-18 · RICHARD LOWENTHAL filed to sell $315.9K2026-08-18 · SARINA TANIMOTO filed to sell $311.2K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $283.6K sold by insiders over 180 days, 114 funds added last quarter, $2.2M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, ARS Pharmaceuticals, Inc. insiders sold a net $283.6K of stock across 210 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Karas Eric
Chief Commercial Officer
SELL
2026-06-12
25,000.0
$250.0K
Fitzpatrick Alexander A
Chief Legal Officer
SELL
2026-06-12
3,355.0
$33.5K
Dorsey Brian
Chief Operating Officer
SELL
2025-11-13
21,828.0
$190.1K
Chakma Justin
Chief Business Officer
SELL
2025-11-12
136,380.0
$1.2M
Chakma Justin
Chief Business Officer
SELL
2025-11-12
30,000.0
$267.3K
210 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 205 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
RA CAPITAL MANAGEMENT, L.P.
10,860,977.0 sh
$87.0M
Rubric Capital Management LP
8,540,861.0 sh
$68.4M
ORBIMED ADVISORS LLC
8,288,510.0 sh
$66.4M
DEERFIELD MANAGEMENT COMPANY, L.P.
7,503,812.0 sh
$60.1M
BlackRock, Inc.
5,311,319.0 sh
$42.5M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
RICHARD LOWENTHAL
FILED 2026-09-03
$115.6K
RICHARD LOWENTHAL
FILED 2026-09-02
$5.0K
SARINA TANIMOTO
FILED 2026-09-01
$272.8K
SARINA TANIMOTO
FILED 2026-08-31
$368.1K
RICHARD LOWENTHAL
FILED 2026-08-20
$148.2K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
ALPS Medical Breakthroughs ETF
$817.6K POSITION · AS OF 2026-02-28
0.6%
BARON DISCOVERY FUND
$8.6M POSITION · AS OF 2026-03-31
0.5%
Knights of Columbus Small Cap Equity Fund
$970.9K POSITION · AS OF 2026-04-30
0.5%
Allspring Small Company Growth Fund
$2.4M POSITION · AS OF 2026-04-30
0.5%
Sit Small Cap Growth Fund
$587.0K POSITION · AS OF 2026-03-31
0.5%
Royce Smaller-Companies Growth Fund
$433.6K POSITION · AS OF 2026-03-31
0.2%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 4 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release
3
Phase 2
1 ACTIVE
1
Phase 4
1 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$9.7M
$10.2M
$4.1M
+113%
—
2024
$7.2M
$14.6M
$3.2M
+93%
—
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$84.3M$89.1M$30.0K$1.3M
OPERATING INCOME$-179.4M$-3.1M$-67.5M$-35.5M
NET INCOME$-171.3M$8.0M$-54.4M$-34.7M
EPS (DILUTED)-1.740.08-0.57-0.87
OPERATING CASH FLOW$-170.9M$13.5M$-59.3M$-40.1M
CASH$41.3M$50.8M$71.0M$210.5M
LONG-TERM DEBT$96.4M$0——
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →